ATM1 Antibody

What epitopes do different commercial ATM1 antibodies recognize?

ATM1 antibodies can target various epitopes depending on their design and intended application. Polyclonal antibodies like ab226985 recognize synthetic peptide regions within human ATM . Some antibodies target the unconserved N-terminal extension (NTE) domain, which has proven useful for generating antibodies with high specificity, as demonstrated in Plasmodium falciparum studies where a 6X-His tagged NTE protein (PfATM1-NTE, 33 kDa) was used to generate rabbit antibodies with high specificity . When selecting an antibody, researchers should consider the conserved nature of target epitopes across species if cross-reactivity is desired.

How do I determine the appropriate ATM1 antibody for my specific organism model?

Selection should be based on sequence homology and validated reactivity. For human samples, antibodies like ab226985 are directly applicable . For studies in parasites like Toxoplasma gondii or Plasmodium falciparum, custom antibodies may be required, as demonstrated in recent Apicomplexa research . For yeast models such as Schizosaccharomyces pombe, specialized antibodies targeting the fission yeast ATM1 protein are available . Always verify sequence homology between your model organism's ATM1 protein and the immunogen used to generate the antibody, particularly focusing on conserved domains if cross-species reactivity is desired.

What is the difference between ATM and ATM1 antibodies in research applications?

This distinction is crucial as they target different proteins with distinct functions. ATM antibodies target the serine/threonine protein kinase mutated in ataxia-telangiectasia, involved in DNA damage response . In contrast, ATM1 antibodies may target:

• The mitochondrial ABC family iron transporter (in yeast and parasites)

• A tumor-associated antigen designated as ATM-1 identified in certain cancer studies

Researchers must clearly distinguish between these targets, as using the incorrect antibody will lead to entirely different biological interpretations.

What are the validated applications for ATM1 antibodies in parasite research?

In Apicomplexa research, ATM1 antibodies have been successfully applied in:

• Immunofluorescence assays (IFAs) - Used to determine subcellular localization of ATM1, confirming mitochondrial localization in both Toxoplasma gondii and Plasmodium falciparum

• Western blotting - Successfully detecting ATM1 protein expression and depletion in parasite models, with ATM1 in P. falciparum running at approximately 123 kDa

• Protein tracking during knockdown experiments - Monitoring protein depletion kinetics following genetic modifications such as conditional knockdown systems

These applications have been instrumental in establishing ATM1's essential role in parasite viability and mitochondrial function.

How should ATM1 antibody dilutions be optimized for Western blotting?

Optimal dilutions vary based on antibody source and target tissue. For human samples, ab226985 has been validated at 1/500 dilution for detecting ATM in human cell lines like HeLa . For parasite studies, antibodies against P. falciparum ATM1-NTE have successfully detected the native protein at approximately 123 kDa . When optimizing:

• Start with manufacturer's recommended dilution

• Perform a dilution series (e.g., 1:250, 1:500, 1:1000)

• Include appropriate controls:

  • Positive control (known ATM1-expressing tissue)

  • Negative control (ATM1-knockdown samples if available)

• Adjust loading amount based on target abundance (e.g., 60 μg whole cell extract was used successfully in HeLa cells)

Note that transmembrane proteins like ATM1 may run at apparent molecular weights slightly different from their calculated sizes .

What controls are essential when using ATM1 antibodies for immunofluorescence?

Rigorous controls are critical for reliable immunofluorescence results with ATM1 antibodies:

• Primary antibody specificity controls:

  • ATM1 knockdown/knockout samples (where feasible)

  • Competitive blocking with immunizing peptide

  • Pre-immune serum control

• Subcellular colocalization markers:

  • For mitochondrial ATM1: Use established markers like mHsp70 or Mitotracker Red

  • For distinguishing from other organelles: Include markers for potentially confounding structures (e.g., apicoplast markers like PfHU in Plasmodium studies)

• Secondary antibody controls:

  • Secondary-only staining to assess non-specific binding

  • Isotype-matched negative control antibodies

In parasite studies, comparative staining across developmental stages has provided additional validation, as demonstrated in P. falciparum asexual blood stages .

How can I validate ATM1 antibody specificity when genetic knockouts are not available?

When genetic knockouts aren't feasible, alternative validation approaches include:

• RNA interference or conditional knockdown systems:

  • shRNA targeting ATM1 (as demonstrated in HeLa cells)

  • Conditional systems like the rapamycin-inducible DiCre system with loxP sites (as used in T. gondii)

  • Vivo-morpholino-mediated knockdown (as used in P. falciparum)

• Mass spectrometry confirmation:

  • Immunoprecipitate proteins using the ATM1 antibody

  • Analyze peptide fragments by mass spectrometry to confirm identity

  • This approach has been used successfully to distinguish between wild-type and mutant ATM proteins

• Multiple antibody approach:

  • Use several antibodies targeting different epitopes of ATM1

  • Concordance between antibodies increases confidence in specificity

  • This approach helped identify a brain-specific ATM protein variant in mouse models

What are common causes of inconsistent ATM1 antibody performance in Western blots?

Several factors can contribute to variable results when detecting ATM1:

• Protein size and processing variations:

  • ATM1 may appear as multiple bands (e.g., unprocessed ~123 kDa form and processed forms)

  • In some studies, two distinct bands have been observed for TgATM1, with a lower 70 kDa band potentially representing a degradation product or processed form

• Sample preparation issues:

  • Insufficient denaturation of transmembrane proteins

  • Inadequate reduction of disulfide bonds (particularly important for ATM-1 tumor antigen, which forms disulfide-linked complexes)

  • Heat sensitivity (ATM-1 immunoreactivity was lost after treatment at 60°C for 30 min)

• Antibody handling:

  • Small volumes of antibody may become entrapped in the vial seal during shipment and storage

  • Repeated freeze-thaw cycles may reduce antibody efficacy

To improve consistency, optimize protein extraction methods specifically for membrane proteins and consider non-reducing conditions if disulfide bonds are structurally important.

How can I distinguish between specific and non-specific bands when detecting ATM1?

Distinguishing specific from non-specific signals requires methodical validation:

• Molecular weight verification:

  • ATM1 in P. falciparum appears at ~123 kDa

  • TgATM1 may show multiple bands including a lower 70 kDa band

  • Tumor-associated ATM-1 exists in multiple forms: ~1,200,000, ~700,000, and ~120,000 Da complexes

• Genetic approaches:

  • Compare with ATM1 knockdown samples (the specific band should decrease in intensity)

  • For inducible systems, assess band intensity at different time points after induction

• Biochemical verification:

  • Enrichment in appropriate subcellular fractions (mitochondrial for canonical ATM1)

  • Peptide competition assays using the immunizing peptide

  • For glycoproteins like tumor-associated ATM-1, verify lectin binding properties (concanavalin A and wheat germ agglutinin binding)

How can ATM1 antibodies be used to investigate iron-sulfur cluster biogenesis in parasites?

ATM1 antibodies have proven valuable in elucidating the role of ATM1 in Fe-S cluster transport:

• Subcellular localization studies:

  • ATM1 antibodies can confirm mitochondrial localization, supporting its role in Fe-S export from mitochondria to cytosol

  • Combined with markers for Fe-S cluster biosynthesis machinery, these studies establish spatial relationships in the biosynthetic pathway

• Temporal analysis during knockdown:

  • Following ATM1 depletion using conditional systems

  • Correlating ATM1 protein levels with Fe-S enzyme activities

  • In T. gondii, ATM1 depletion led to growth defects visible within 24 hours, with increasingly severe effects at 48 and 72 hours

• Compensatory mechanism investigation:

  • Detecting changes in expression of other Fe-S transport components

  • Assessing stress responses triggered by ATM1 depletion

This approach has demonstrated that ATM1 serves as an essential bridge between mitochondrial and cytosolic Fe-S biogenesis in Apicomplexa .

What experimental design is recommended for using ATM1 antibodies in cancer biomarker studies?

Based on previous cancer research with ATM-1 tumor antigen , a comprehensive experimental approach would include:

• Sample preparation standardization:

  • Process serum samples consistently to preserve the various molecular weight forms of ATM-1

  • Consider the temperature sensitivity of the antigen (avoid temperatures above 60°C)

• Detection method optimization:

  • Sandwich enzyme immunoassay has proven effective for clinical samples

  • Consider multiple antibody pairs targeting different epitopes

• Control cohort design:

  • Include diverse cancer types (previous studies found varying positivity rates: breast cancer 67%, hepatocellular carcinoma 83%, gastric cancer 58%, lung cancer 41%)

  • Include non-malignant inflammatory conditions as controls (studies found 0% positivity in systemic lupus erythematosus and rheumatoid arthritis)

  • Include hematological malignancies (previously showed 0% positivity)

• Molecular characterization:

  • Characterize the different molecular weight forms (~1,200,000, ~700,000, and ~120,000 Da)

  • Assess glycosylation patterns through lectin binding studies

This comprehensive approach would build upon previous findings suggesting ATM-1 as a potential biomarker for specific solid tumors.

How can ATM1 antibodies contribute to understanding mitochondrial dysfunction in parasite drug resistance?

ATM1 antibodies can provide insights into mitochondrial adaptations during drug resistance development:

• Expression level analysis:

  • Compare ATM1 protein levels between drug-sensitive and resistant parasite strains

  • Correlate with mitochondrial functional parameters

• Localization pattern changes:

  • Assess whether drug resistance alters ATM1 distribution within mitochondria

  • Co-localize with markers of mitochondrial stress or fragmentation

• Functional studies with conditional systems:

  • Use antibodies to confirm knockdown efficiency in conditional systems

  • Compare phenotypic consequences of ATM1 depletion in sensitive versus resistant parasites

  • In P. falciparum, ATM1 knockdown resulted in growth delays at 96 and 108 hours post-treatment

• Drug response monitoring:

  • Track ATM1 expression changes following drug exposure

  • Correlate with mitochondrial morphology changes (though initial studies in P. falciparum did not show apparent alterations in mitochondrial morphology after ATM1 depletion)

How should researchers interpret conflicting results between different ATM1 antibodies?

Discrepancies between antibodies should be systematically investigated:

• Epitope mapping analysis:

  • Different antibodies may recognize distinct epitopes that are differentially accessible

  • In brain tissue studies of ATM mutant mice, antibodies targeting different epitopes gave contrasting results: Y170 showed no immunoreactivity while 2C1A1 and 5C2 detected protein expression

• Protein isoform consideration:

  • Tissue-specific ATM1 variants may exist, as demonstrated in the ATM studies where brain-specific ATM protein was detected

  • Post-translational modifications may mask certain epitopes

• Methodological approach:

  Antibody	Application with inconsistent results	Resolution strategy
  Y170	Failed to detect brain-specific ATM in mutant mice	Confirm with MS analysis
  2C1A1	Detected brain-specific ATM in mutant mice	Validate with IP-MS
  5C2	Detected brain-specific ATM in mutant mice	Compare epitope location

• Validation through orthogonal techniques:

  • Mass spectrometry can provide unbiased confirmation of protein identity and epitope presence

  • Genetic approaches (creating epitope-tagged versions) can resolve ambiguities

What statistical approaches are recommended when quantifying ATM1 expression changes in knockdown experiments?

Robust statistical analysis is essential for reliable interpretation:

• Normalization strategies:

  • Normalize to stable reference proteins (actin was used successfully in P. falciparum studies)

  • Consider multiple reference proteins, especially when studying conditions that might affect commonly used controls

• Quantification methods:

  • For western blots: Densitometry with background subtraction

  • For immunofluorescence: Integrated density measurements with background correction

• Statistical tests appropriate for time-course experiments:

  • Repeated measures ANOVA for comparing protein levels across multiple time points

  • Area under the curve analysis for cumulative effects over time

  • In P. falciparum studies, ATM1 levels showed significant reduction (57% decrease) at 96 hours post-treatment but returned to normal by 144 hours

• Power analysis considerations:

  • Preliminary data from P. falciparum suggests high variability in knockdown efficiency

  • Multiple biological replicates are essential (minimum n=3)